Additional file 1 of SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia
Creators: name: Karachaliou, Marianna
name: Moncunill, Gemma
name: Espinosa, Ana
name: Castaño-Vinyals, Gemma
name: Rubio, Rocío
name: Vidal, Marta
name: Jiménez, Alfons
name: Prados, Esther
name: Carreras, Anna
name: Cortés, Beatriz
name: Blay, Natàlia
name: Bañuls, Marc
name: Pleguezuelos, Vanessa
name: Melero, Natalia Rodrigo
name: Serra, Pau
name: Parras, Daniel
name: Izquierdo, Luis
name: Santamaría, Pere
name: Carolis, Carlo
name: Papantoniou, Kyriaki
name: Goldberg, Ximena
name: Aguilar, Ruth
name: Garcia-Aymerich, Judith
name: de Cid, Rafael
name: Kogevinas, Manolis
name: Dobaño, Carlota
Publisher: name: figshare
Year: 2022
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Table S1. Characteristics of participants with breakthrough infections, post-vaccination. Table S2. Allocation of vaccinated and non-vaccinated participants with evidence of infection according to the criterion of infection fulfilled. Table S3. Fold change (FC) (95% CI) in antibody levels within one year after infection estimated using two repeated samples among decayers. Estimates are based on linear mixed-effects models. Table S4. Spearman correlations for RBD antigen. All participants, n=1,076. Darker red=stronger association. Table S5. Cross tabulation between serostatus to RBD of Wuhan variant with the RBD of Alpha, Beta Gamma and Delta variants. Table S6. Characteristics of non-responders (seronagetive or with an undetermined status) to vaccination. Table S7. Association (fold change FC and 95% CI and p-values) between each determinant with log10 antibody leves in vaccinated people after adjusting each model for time since last vaccination and number of doses. Participants with any vaccination excluding Janssen (n=923). Table S8. P-values for comparisons related to Figs. 3 and 5 and Figure S6. Figure S1. Dates and density of positive viral detection tests, sampling in 2020 (1st serological assessment) and 2021 (2nd serological assessment) and receipt of 1st vaccine dose in the study population (n=1,076). Figure S2. Venn diagram illustrating overlap between sustainer groups of IgA or IgG antibodies against nucleoprotein and spike antigens, among all infected unvaccinated participants (n=64). Figure S3. Differences in IgG antibody responses against RBD between Wuhan, Alpha, Beta, Gamma and Delta variant among vaccinated people. All differences were statistically significant apart from Delta vs Wuhan (p=0.861) and Alpha vs Wuhan (p=0.051). Figure S4. Generalized additive models for associations of days since vaccination with antibody responses to the six isotype-antigen combinations in infected (red) and naïve (blue) participants after first or second dose in people vaccinated by Vaxzevria (a), Comirnaty (b) or Spikevax (c). Fitted lines after adjustment for participant’s age. Plus symbols (+) represent measured responses for a specific participant. Figure S5. Differences in antibody responses by infection and/or vaccination and number of doses in people vaccinated with Comirnaty (a), Spikevarx (b), Vaxzevria (c) of Janssen COVID-19 vaccine (d). Figure S6. Differences in IgM responses by infection and/or vaccination and number of doses. Table S8 presents corresponding p-values.